Abstract:Developing novel therapeutics and diagnostic tools based upon an understanding of neuroplasticity is critical in order to improve the treatment and ultimately the prevention of a broad range of nervous system disorders. In the case of mood disorders, such as major depressive disorder (MDD) and bipolar disorder (BPD), where diagnoses are based solely on nosology rather than pathophysiology, there exists a clear unmet medical need to advance our understanding of the underlying molecular mechanisms and to develop fundamentally new mechanism experimental medicines with improved efficacy. In this context, recent preclinical molecular, cellular, and behavioral findings have begun to reveal the importance of epigenetic mechanisms that alter chromatin structure and dynamically regulate patterns of gene expression that may play a critical role in the pathophysiology of mood disorders. Here, we will review recent advances involving the use of animal models in combination with genetic and pharmacological probes to dissect the underlying molecular mechanisms and neurobiological consequence of targeting this chromatin-mediated neuroplasticity. We discuss evidence for the direct and indirect effects of mood stabilizers, antidepressants, and antipsychotics, among their many other effects, on chromatin-modifying enzymes and on the epigenetic state of defined genomic loci, in defined cell types and in specific regions of the brain. These data, as well as findings from patient-derived tissue, have also begun to reveal alterations of epigenetic mechanisms in the pathophysiology and treatment of mood disorders. We summarize growing evidence supporting the notion that selectively targeting chromatin-modifying complexes, including those containing histone deacetylases (HDACs), provides a means to reversibly alter the acetylation state of neuronal chromatin and beneficially impact neuronal activity-regulated gene transcription and mood-related behaviors. Looking beyond current knowledge, we discuss how high-resolution, whole-genome methodologies, such as RNA-sequencing (RNA-Seq) for transcriptome analysis and chromatin immunoprecipitation-sequencing (ChIP-Seq) for analyzing genome-wide occupancy of chromatin-associated factors, are beginning to provide an unprecedented view of both specific genomic loci as well as global properties of chromatin in the nervous system. These methodologies when applied to the characterization of model systems, including those of patient-derived induced pluripotent cell (iPSC) and induced neurons (iNs), will greatly shape our understanding of epigenetic mechanisms and the impact of genetic variation on the regulatory regions of the human genome that can affect neuroplasticity. Finally, we point out critical unanswered questions and areas where additional data are needed in order to better understand the potential to target mechanisms of chromatin-mediated neuroplasticity for novel treatments of mood and other psychiatric disorders.

Epigenetic Regulation in Psychosomatics and Psychotherapy

Epigenetic Basis of Psychiatric Disorders: A Narrative Review

A perspective on epigenomic aging processes in the human brain and their plasticity in patients with mental disorders - a systematic review

Epigenetic Signaling in Psychiatric Disorders

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Stress, epigenetics and depression: A systematic review

Epigenetic mechanisms of stress and depression.

An epigenomics approach to individual differences and its translation to neuropsychiatric conditions

Psychosomatics: Communication of the Central Nervous System through Connection to Tissues, Organs, and Cells

Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential

Unlocking the epigenetic symphony: histone acetylation's impact on neurobehavioral change in neurodegenerative disorders

Epigenetic modulators provide a path to understanding disease and therapeutic opportunity

Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases

Epigenetic signaling in psychiatric disorders: stress and depression

Epigenetics of Ageing and Psychiatric Disorders

Epigenetic mechanisms in mood disorders: targeting neuroplasticity

Epigenetic Regulation in Schizophrenia: Focus on Methylation and Histone Modifications in Human Studies

From Epigenetic Associations to Biological and Psychosocial Explanations in Mental Health

Epigenetic Research in Neuropsychiatric Disorders: the "Tissue Issue"

PSORIASIS AND MENTAL HEALTH: A PSYCHODERMATOLOGICAL APPROACH WITH AN EMPHASIS ON PSYCHOTHERAPY

Epigenetics and depressive disorders: a review of current progress and future directions